Sovaldi Hepatitis C Treatment In India
Sofosbuvir is gilead to develop new drugs for the treatment of chronic hepatitis c, on December 6, 2013, the United States food and drug administration approved in the United States, on January 16, 2014, the European drug administration approval listed on the European Union. Has not been listed in China. Most of blockbuster drugs approved by the FDA in 2013.
Sofosbuvir is first without joint interferon can is safe and effective drug for the treatment of certain types of hepatitis c. Clinical trials confirm for type 1 and 4 c, the drug combination of polyethylene glycol (peg) interferon and ribavirin overall sustained virological response (SVR) is as high as 90%; In view of the type 2 c, the drug plus ribavirin SVR is 89% - 95%; In view of the 3 c, the drug plus ribavirin 24 weeks of SVR is 84%.
Taking Sofosbuvir must on time every day, must not leak, at the same time every day. 2, eat in the morning and evening eat impact is not big, usually before meals or best one hour after a meal to take effect. 3, use during Sofosbuvir of avoid by all means do not drinking, drinking every day more than 5 ml can affect drug efficacy. 4, severe renal injury/dialysis patients must consulting medical scheme, known, according to data from SuoFei cloth wei metabolites in patients with renal insufficiency or renal failure have accumulated in the body.
Hepatitis c can be cured, in order to use Sofosbuvir treatment of hepatitis c, because the replication of hepatitis c rate of 12 room, so at the end of the period of treatment discontinuation three months went to the hospital to check the degree of hepatitis c virus (HCV) drops, if still cannot detect the virus, then c completely cured. This is a common standard of judgment, because three months without recurrence after the drug was stopped, the probability of relapse back almost to zero.